39.40
+0.315(+0.81%)
Currency In USD
| Previous Close | 39.09 |
| Open | 38.92 |
| Day High | 40.2 |
| Day Low | 37.95 |
| 52-Week High | 62.4 |
| 52-Week Low | 29.17 |
| Volume | 2.49M |
| Average Volume | 1.84M |
| Market Cap | 7.34B |
| PE | -9.83 |
| EPS | -4.01 |
| Moving Average 50 Days | 37.77 |
| Moving Average 200 Days | 43.63 |
| Change | 0.32 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $1,363.32 as of June 01, 2025 at a share price of $39.4. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $2,384.99 as of June 01, 2025 at a share price of $39.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has bee
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
GlobeNewswire Inc.
Apr 30, 2025 8:05 PM GMT
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report fin
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
GlobeNewswire Inc.
Apr 27, 2025 4:05 PM GMT
Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancerREDWOOD CITY, Calif., April 27, 2025 (GL